Piramal Pharma to invest in baby care brand Little's, expects strong sales growth

By

Isabelle Crossley

Published
Jan 20, 2022

Piramal Group’s Piramal Pharma plans to focus its investments in its baby care brand Little's which it expects to contribute to doubling sales in its consumer healthcare division in the coming two to three years. 

The business expects its consumer healthcare division to reach Rs 1,000 crore in sales in the coming few years, driven by sales growth through its brand Little’s, the Economic Times reported. The business plans to focus its investments on the brand and expand its product selection in order to achieve this. 
 
“Our Little's brand is where we are putting a lot of investment,” the business’ executive director Nandini Piramal told the Economic Times in an interview. “We are still a young country, that is still growing in terms of children, that's one where we are putting our effort behind. We think it can grow into a Rs 500 crore brand in [the] next few years.”

Baby care brand Little's retails products including personal care goods for babies, diapers, laundry care goods, and toys, among others. Piramal Pharma expects Little’s to report sales of Rs 100 crore by the end of the 2022 financial year. 
 
Piramal Pharma have made a number of investments recently and invested Rs 101.77 crore in Hyderabad-based business Yapan Bio last month for a 27.78% stake, Express Pharma reported. The acquisition of the business, which is involved in manufacturing vaccines, was designed to augment Piramal’s Contract Development and Manufacturing Organisation business.